
 **(HFTI) Henry Ford Transplant Institute Lecture Series 2021 | 4/19/2021 12:00:00 PM Webex**

The intent of the Transplant Institute Lecture Series is to update all transplant disciplines on the stringent federal rules and regulations, to keep staff informed of new and evolving information, quality initiatives, infectious disease updates, immunosuppression protocols, research projects, cancer research and health maintenance. These educational lectures will include all transplant disciplines and the topics will cover diversity/equity, quality, policies, infectious disease, immunosuppression, research, organ specific topics, and cancer and health maintenance.

**Program Goal**

1 Share the latest quality trends and expectations necessary for transplant programs

**Target Audience** Transplant Institute

**Faculty**

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Name of commercial interest/Nature of relationship** |
| Susan Haloostock, None | Activity Coordinator | Nothing to disclose - 02/05/2021 |
| Linda Murray, BBA | CME Specialist | Nothing to disclose - 06/17/2020 |
| Marwan Abouljoud, MD | Course Director,Faculty | Nothing to disclose - 02/05/2021 |
| Lisa Maclean, MD | Faculty | Nothing to disclose - 04/08/2021 |

**ACCREDITATION STATEMENT: Henry Ford Health System** is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

**DESIGNATION STATEMENT: Henry Ford Health System** designates this educational activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

**FACULTY/PLANNING COMMITTEE DISCLOSURE STATEMENT:** In Compliance with the ACCME Standards for Commercial Support, all individuals in a position to control/influence the content of this activity are required to disclose relevant financial interests of their own or spouse or partners with any ACCME defined commercial interests for the past 24 months and/or any non-FDA approved use of a drug or a device that is included in the presentation. All relevant financial relationships have been mitigated.